Rimegepant

Rimegepant
Clinical data
Other names	BHV-3000, BMS-927711
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate;
CAS Number	1289023-67-1;
PubChem CID	51049968;
ChemSpider	27289072;
UNII	997WVV895X;
KEGG	D10662;
CompTox Dashboard (EPA)	DTXSID70156003 ;
Chemical and physical data
Formula	C28H28F2N6O3
Molar mass	534.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;
	InChI InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1; Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N;

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb,[1] it is currently under development by Biohaven Pharmaceuticals.[2]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[3]

References

"Drug Profile: Rimegepant". Adis Insight.
"Rimegepant (BHV-3000) – for acute treatment of Migraine". Biohaven Pharmaceuticals.
Diener, Hans-Christoph; Charles, Andrew; Goadsby, Peter J; Holle, Dagny (2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet Neurology. 14 (10): 1010. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Drug Profile: Rimegepant". Adis Insight.

[2] "Rimegepant (BHV-3000) – for acute treatment of Migraine". Biohaven Pharmaceuticals.

[3] Diener, Hans-Christoph; Charles, Andrew; Goadsby, Peter J; Holle, Dagny (2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet Neurology. 14 (10): 1010. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.